News & Events

The value of our clients' news is directly related to the macro events and trends shaping the life sciences and healthcare industry. To appreciate one, you must fully understand the other.

Tiberend Strategic Advisors invites those interested in our firm and the companies we represent to access our News Feed and register for our Events Calendar.  Doing so, you will be assured to receive actionable information on the companies and trends that are defining the life sciences and healthcare space.

News Feed

     

Events Calendar

May 10 2017

KemPharm, Inc. Reports First Quarter 2017 Results

 

May 10 2017

CorMedix Inc. Reports First Quarter Financial Results and Provides Business Update

May 10 2017

Galena Biopharma Reports First Quarter 2017 Financial Results

 

May 9 2017

CorMedix Inc. Demonstrates Sensitivity of Emerging Global Health Threat Candida auris to Taurolidine

 

May 5 2017

CorMedix Inc. to Report First Quarter 2017 Financial Results and Provide Business Update

May 4 2017

Rebiotix’s Phase 3 Ready RBX2660 to be Featured in Multiple Sessions at Digestive Disease Week 2017

May 4 2017

CorMedix Inc. Announces Closing of Public Offering of Common Stock and Warrants and Underwriter’s Exercise in Full of Over-Allotment Option

 

May 2 2017

CureVac Appoints Daniel Menichella as CEO of CureVac Inc., the Company’s US Subsidiary

May 1 2017

Cantex Pharmaceuticals, Inc. Announces Initiation of Phase II Clinical Development for CX-02 in Recurrent Glioblastoma

April 28 2017

CorMedix Inc. Increases Previously Announced Public Offering to $12.1 Million

 

April 27 2017

CorMedix Inc. Announces $10 Million Underwritten Public Offering

Apr 20 2017

CorMedix Inc. Reports Update on Neutrolin® Phase 3 LOCK-IT 100 Clinical Trial

 

April 19 2017

Cantex Pharmaceuticals to Present Overview of CX-02 at the World Orphan Drug Congress

Apr 12 2017

CorMedix Inc. Secures First European Commercial Collaboration for Neutrolin

 

Apr 11 2017

Rebiotix Reports Positive Top Line Data from Open-Label Phase 2 Trial of RBX2660 in Recurrent Clostridium difficile

Apr 7 2017

Lakewood-Amedex Advances Novel Bisphosphocin® Nu-8 Compound Based on Encouraging Pre-Clinical Results

 

Apr 4 2017

Cantex Pharmaceuticals, Inc. Announces Poster Presentation at AACR Annual Meeting 2017

 

Apr 4 2017

Galena Biopharma Presents Positive Interim Safety Data on the NeuVax™ (nelipepimut-S) Clinical Trial in Combination with Trastuzumab in High-Risk HER2 3+ Patients at the AACR Annual Meeting 2017

Mar 30 2017

Promentis Pharmaceuticals, Inc. Announces $26M Series C Financing and Elects Four New Board Members

Mar 30 2017

Enteris to Present at BioCentury’s Future Leaders

 

Mar 28 2017

Ehave Announces the Appointment of Dave Goyette as Chief Technology Officer

Mar 27 2017

KemPharm to Present at the 2nd Annual Neuroscience Biopartnering and Investment Forum

Mar 26 2017

Lakewood-Amedex Announces appointment of Chief Medical Officer and Chief Scientific Officer to enhance drug development and clinical trials program

 

Mar 22 2017

TapImmune to Participate in Two Upcoming Investor and Industry Conferences

Mar 21 2017

EnGeneIC Doses First Patient in U.S. Phase 1 Clinical Study of Targeted EDV™ Nanocells in Recurrent Glioblastoma Multiforme

 

Mar 17 2017

CorMedix Inc. Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update

 

Mar 17 2017

Galena Biopharma Presents Positive Final GALE-301 (E39) Phase 1/2a Clinical Trial Data

Mar 16 2017

KemPharm Presents Clinical Data for Opioid Prodrug Candidates at American Academy of Pain Medicine’s Annual Meeting

 

Mar 15 2017

Galena Biopharma Reports Fourth Quarter and Year End 2016 Financial Results and Provides a Corporate Update

 

Mar 14 2017

TapImmune Provides Year End 2016 Corporate and Clinical Update

Mar 9 2017

KemPharm, Inc. Reports Fourth Quarter and Year End 2016 Results

Mar 2 2017

EnGeneIC Receives FDA Orphan Drug Designation for Targeted EDV™ Nanocells to Treat Glioblastoma Multiforme

 

Mar 2 2017

CorMedix Inc. Appoints John L. (Jack) Armstrong to Senior Leadership Team

Mar 2 2017

Rebiotix to Present at Two Investor Conferences

Feb 15 2017

TapImmune Advances TPIV 200 Phase 2 Triple-Negative Breast Cancer Trial After Favorable DSMB Safety Review

 

Feb 14 2017

Ehave and MedReleaf Enter Partnership to Optimize the Therapeutic Potential of Medical Cannabis Products

Feb 7 2017

KemPharm to Present at Upcoming Investor Conferences

 

Feb 7 2017

TapImmune Expands Intellectual Property On PolyStart Platform For Use In Next-Generation T-Cell Vaccines

 

Feb 6 2017

Rebiotix to Present at BIO CEO & Investor Conference

Feb 6 2017

Galena Biopharma Reports Positive Outcome from the Data Safety Monitoring Board on the Two NeuVax™ (nelipepimut-S) Clinical Trials in Combination with Trastuzumab

Jan 30 2017

Ferring Pharmaceuticals and Enteris BioPharma Enter License Agreement to Develop an Oral Formulation of a Peptide-based Injectable Therapeutic

 

Jan 25 2017

Enteris BioPharma Enters into Agreement with Nordic Bioscience’s KeyBioscience to Develop Orally Delivered Metabolic Peptide

Jan 23 2017

Enteris BioPharma Enters Agreement with Sanofi to Develop Investigational Oral Therapeutic for Type 2 Diabetes

 

Jan 20 2017

CureVac’s CEO, Ingmar Hoerr, Appointed by European Commission to High Level Group

 

Jan 11 2017

CureVac Provides Clinical Update at 35th Annual J.P. Morgan Healthcare Conference

Jan 11 2017

Ehave Appoints New Members to its Board of Directors

 

Jan 9 2017

Aridis Pharmaceuticals Receives Award from the Cystic Fibrosis Foundation Therapeutics to Advance Panaecin™

 

Jan 9 2017

KemPharm Reports Positive Data from Phase 1 Intranasal Pharmacokinetic Study of KP511, An Investigational Prodrug of Hydromorphone for the Treatment of Pain

Jan 5 2017

Aridis Pharmaceuticals Reports Positive Clinical Data from Phase 1/2a Study of Human Monoclonal Antibody AR-301 for Treating Pneumonia

 

Jan 5 2017

CorMedix to Present at Biotech Showcase 2017

Jan 5 2017

Galena Biopharma to Provide Corporate and Clinical Update and 2017 Outlook During Presentation at Biotech Showcase 2017

 

Jan 4 2017

Rebiotix Treats First Patient in Phase 1 Study of RBX7455, an Orally Delivered Broad-Spectrum Non-Frozen Microbiota Capsule for Recurrent Clostridium difficile Infection

Jan 4 2017

KemPharm to Present at Biotech Showcase 2017

 

Jan 4 2017

ContraVir Pharmaceuticals to Present at Biotech Showcase 2017

 

Jan 3 2017

ContraVir Awarded Grant from Canada's National Research Council to Advance CRV431 for the Treatment of Hepatitis B

Dec 28 2016

CureVac to Present at the J.P. Morgan 35th Annual Healthcare Conference 2017

 

Dec 28 2016

Galena Biopharma Confirms Regulatory Pathway for GALE-401 (Anagrelide Controlled Release)

Dec 20 2016

KemPharm Granted "Fast Track" Designation for KP201/IR

 

Dec 19 2016

ContraVir Expands Phase 2a Trial of Tenofovir Exalidex (Formerly CMX157) to Include Doses above 100 mg

Dec 15 2016

ContraVir Appoints Business Development Executive Tamar Howson to its Board of Directors

 

Dec 14 2016

KemPharm’s KP415, An Investigational Prodrug of D-Methylphenidate, Completes Phase 1 Proof-of-Concept Trial for the Treatment of ADHD

 

Dec 14 2016

Multi-Health Systems and Ehave Inc. Enter Partnership to Integrate Psychological Assessments into the Ehave Connect Mental Health Digital Informatics Platform

Dec 14 2016

Galena Biopharma Announces the Phase 2 Clinical Trial of NeuVax™ (nelipepimut-S) in Ductal Carcinoma in Situ (DCIS) is Open for Enrollment and Screening Patients

 

Dec 13 2016

Medac Pharma, Inc. Appoints Industry Veteran as Vice President of Sales in the U.S.

Dec 12 2016

Galena Biopharma Presented Two Posters at the San Antonio Breast Cancer Symposium

 

Dec 8 2016

ContraVir's Cyclophilin Inhibitor CRV431 Potently Inhibits Essential Pathway in Hepatitis B

 

Nov 30 2016

Galena Biopharma to Present Two Posters at the San Antonio Breast Cancer Symposium

Nov 29 2016

Ehave Announces DTC Eligibility of its Common Shares

 

Nov 22 2016

Ehave to Host First Annual Shareholder Meeting

 

Nov 21 2016

Ehave Inc. Announces Listing on the OTCQB Under the Trading Symbol EHVVF

Nov 21 2016

Ehave Inc. Appoints Prateek Dwivedi as President and Chief Executive Officer

 

Nov 15 2016

Ganaxolone and Diazepam Administered Intravenously Synergistically Block Seizures in Animal Model of Status Epilepticus

 

Nov 14 2016

Galena Biopharma Presents GALE-301/GALE-302 Phase 1b Data at the Society for Immunotherapy of Cancer Conference 2016

Nov 10 2016

CorMedix Inc. Reports Third Quarter 2016 Financial Results and Provides Business Updates

 

Nov 9 2016

Galena Biopharma Reports Third Quarter 2016 Financial Results and Provides a Corporate Update

Nov 9 2016

KemPharm, Inc. Reports Third Quarter 2016 Results

 

Nov 8 2016

CureVac Secures an Additional $29.5 Million From Two New Investors

 

Nov 8 2016

CureVac Receives Broad Patent for RNAntibody® Technology

Nov 7 2016

Aytu BioScience Provides First Fiscal Quarter 2017 Business Update

 

Nov 7 2016

ContraVir to Present at AASLD's The Liver Meeting® 2016

 

Nov 3 2016

Aytu BioScience to Provide Fiscal First Quarter 2017 Business Update

 

Nov 3 2016

KemPharm Appeals FDA Complete Response Letter on Apadaz™ by Initiating a Formal Dispute Resolution Process

 

Nov 3 2016

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2016 Financial Results

 

Nov 3 2016

Galena Biopharma Appoints Stephen F. Ghiglieri as Executive Vice President and Chief Financial Officer

 

Nov 1 2016

KemPharm, Inc. to Report Third Quarter 2016 Results

View more client news »